Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Financial News

Celularity debuts to develop placenta-based cell therapies

August 21, 2017 11:56 PM UTC

Celularity Inc. (Warren, N.J.) launched with an undisclosed series A round, as well as assets and IP, from Sorrento Therapeutics Inc. (NASDAQ:SRNE), United Therapeutics Corp. (NASDAQ:UTHR), Human Longevity Inc. (San Diego, Calif.) and additional undisclosed investors.

The newco is developing placenta-derived cell therapies to treat cancer and chronic and degenerative diseases...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article